Neurocrine Biosciences
NBIX
#1542
Rank
HK$84.45 B
Marketcap
HK$847.01
Share price
-0.07%
Change (1 day)
-23.65%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Operating Margin for Neurocrine Biosciences (NBIX)

Operating Margin as of March 2025 (TTM): 20.63%

According to Neurocrine Biosciences 's latest financial reports and stock price the company's current Operating Margin is 20.63%. At the end of 2024 the company had an Operating Margin of 20.63%.

Operating Margin history for Neurocrine Biosciences from 2001 to 2024

Operating Margin at the end of each year

Year Operating Margin Change
202420.63%17.25%
202317.60%22.48%
202214.37%60.62%
20218.95%-12.31%
202010.20%72.9%
20195.90%22.12%
20184.83%-105.48%
2017-88.19%-90.62%
2016-940.60%109.1%
2015-449.84%
2013-1,578.97%-16797.76%
20129.46%-80.52%
201148.53%-304.06%
2010-23.78%-98.62%
2009-1,728.34%-22.47%
2008-2,229.26%-86.84%
2007-16,936.19%6098.17%
2006-273.25%1425.49%
2005-17.91%-66.61%
2004-53.65%147.89%
2003-21.64%-95.87%
2002-523.89%487.29%
2001-89.21%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
8.96%-56.57%๐Ÿ‡บ๐Ÿ‡ธ USA
68.75% 233.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
-662.26%-3,310.18%๐Ÿ‡บ๐Ÿ‡ธ USA
28.15% 36.45%๐Ÿ‡บ๐Ÿ‡ธ USA
6.59%-68.06%๐Ÿ‡บ๐Ÿ‡ธ USA
12.60%-38.92%๐Ÿ‡บ๐Ÿ‡ธ USA
-3.61%-117.50%๐Ÿ‡บ๐Ÿ‡ธ USA
-1,576.98%-7,744.11%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.